Trial intelligence / Profile preview

TMC435350 with or without peginterferon alfa-2a and ribavirin in genotype 1 hepatitis C

2007-003289-16Phase 2Completed

Sponsor
Tibotec
Start
Oct 2007
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial in hepatitis C virus infection comparing TMC435350 arm with Placebo arm (2 arms). Primary endpoints: Primary antiviral efficacy endpoint, Safety and tolerability and 1 more. Started Oct 2007; status: completed.

02

Drugs

simeprevir
03

Conditions

hepatitis C virus infection

Beyond the preview

Go deeper on 2007-003289-16.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2007-003289-16.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call